Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study

被引：7
|
作者：
Cohen, Jonathon B. [1 ]
Kuruvilla, John [2 ,3 ]
Engert, Andreas [4 ]
Ansell, Stephen M. [5 ]
Younes, Anas [6 ]
Lee, Hun Ju [7 ]
Trneny, Marek [8 ,9 ]
Savage, Kerry J. [10 ]
Ramchandren, Radhakrishnan [11 ]
Collins, Graham P. [12 ]
Zinzani, Pier Luigi [13 ]
De Boer, Jan Paul [14 ]
Shipp, Margaret A. [15 ]
Santoro, Armando [16 ]
Timmerman, John M. [17 ]
Sacchi, Mariana [18 ]
Sy, Oumar [18 ]
Armand, Philippe [19 ]
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[2] Univ Toronto, Toronto, ON, Canada
[3] Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Univ Hosp Cologne, Cologne, Germany
[5] Mayo Clin, Rochester, MN USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[8] Charles Univ Prague, Prague, Czech Republic
[9] Gen Univ Hosp Prague, Prague, Czech Republic
[10] British Columbia Canc, Vancouver, BC, Canada
[11] Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[12] Churchill Hosp, Oxford Canc & Haematol Ctr, Oxford, England
[13] Univ Bologna, Inst Hematol L e A Seragnoli, Bologna, Italy
[14] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands
[15] Dana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA 02115 USA
[16] Humanitas Univ, Humanitas Canc Ctr, Rozzano Milan, Italy
[17] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA
[18] Bristol Myers Squibb, Princeton, NJ USA
[19] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-114502
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2932
引用
收藏
页数：4
相关论文
共 50 条
  • [41] A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma
    Lepik, Kirill V.
    Fedorova, Liudmila V.
    Kondakova, Elena V.
    Zalyalov, Yuri R.
    Babenko, Elena V.
    Lepik, Elena E.
    Kotselyabina, Polina V.
    Beynarovich, Anastasia V.
    Popova, Marina O.
    Volkov, Nikita P.
    Stelmakh, Lilia V.
    Baykov, Vadim V.
    Moiseev, Ivan S.
    Mikhailova, Natalia B.
    Kulagin, Alexander D.
    Afanasyev, Boris V.
    HEMASPHERE, 2020, 4 (05):
  • [42] LONG-TERM FOLLOW-UP RESULTS OF AN ONGOING PIVOTAL STUDY OF BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA (HL)
    Smith, S.
    Chen, R.
    Gopal, A.
    Ansell, S.
    Rosenblatt, J.
    Savage, K.
    Connors, J.
    Engert, A.
    Larsen, E.
    Sievers, E.
    Younes, A.
    HAEMATOLOGICA, 2012, 97 : 456 - 456
  • [43] Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study
    Davids, Matthew S.
    Roberts, Andrew W.
    Kenkre, Vaishalee P.
    Wierda, William G.
    Kumar, Abhijeet
    Kipps, Thomas J.
    Boyer, Michelle
    Salem, Ahmed Hamed
    Pesko, John C.
    Arzt, Jennifer A.
    Mantas, Margaret
    Kim, Su Y.
    Seymour, John F.
    CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4690 - 4695
  • [44] Magrolimab in Combination With Rituximab in Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: 3-Year Follow-up Results From a Phase 1/2 Trial
    Amitkumar, Mehta
    Leslie, Popplewell
    Collins, Graham P.
    Sonali, Smith
    Ian, Flinn
    Bartlett, Nancy S.
    Nilanjan, Ghosh
    Carolc, O'Hear
    Yanan, Huo
    Bertha, Villa
    Indu, Lal
    Ranjana, Advani
    Mark, Roschewski
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S21 - S21
  • [45] Longer-Term Follow-Up of a Phase 2 Study (CheckMate 063) of Nivolumab in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
    Horn, Leora
    Rizvi, Naiyer A.
    Mazieres, Julien
    Planchard, David
    Stinchcombe, Thomas E.
    Dy, Grace K.
    Antonia, Scott J.
    Lena, Herve
    Minenza, Elisa
    Mennecier, Bertrand
    Otterson, Gregory A.
    Campos, Luis T.
    Gandara, David R.
    Levy, Benjamin P.
    Nair, Suresh G.
    Zalcman, Gerard
    Wolf, Juergen
    Paik, Paul
    Li, Ang
    Xu, Dong
    Neely, Jaclyn
    Qi, Zhenhao
    Harbison, Christopher
    Lynch, Mark
    Ramalingam, Suresh S.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S175 - S176
  • [46] NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOID MALIGNANCIES AND CLASSICAL HODGKIN LYMPHOMA: UPDATED SAFETY AND EFFICACY RESULTS OF A PHASE 1 STUDY (CA209-039)
    Armand, P.
    Timmerman, J.
    Lesokhin, A.
    Halwani, A.
    Millenson, M.
    Schuster, S.
    Gutierrez, M.
    Scott, E.
    Cattry, D.
    Freeman, G.
    Chapuy, B.
    Ligon, A.
    Rodig, S.
    Zhu, L.
    Grosso, J.
    Simon, J.
    Shipp, M.
    Cohen, A.
    Lebovic, D.
    Dhodapkar, M.
    Avigan, D.
    Ansell, S.
    Borrello, I.
    HAEMATOLOGICA, 2015, 100 : 323 - 323
  • [47] Nivolumab, Brentuximab Vedotin, and Bendamustine as Response-Adapted Treatment for Relapsed or Refractory Hodgkin Lymphoma in Children, Adolescents and Young Adults: Results from the Standard-Risk Cohort of the Phase 2 Checkmate 744 Study
    Harker-Murray, P.
    Leblanc, T.
    Mascarin, M.
    Mauz-Koerholz, C.
    Michel, G.
    Cooper, S.
    Beishuizen, A.
    Leger, K.
    Garaventa, A.
    Buffardi, S.
    Brugieres, L.
    Kelly, K.
    Cole, P.
    Drachtman, R.
    Galderisi, F.
    Sacchi, M.
    Francis, S.
    Daw, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 89 - 90
  • [48] Sintilimab for relapsed/refractory classical Hodgkin's lymphoma: Long-term follow-up on the multicenter, single-arm phase II ORIENT-1 study.
    Su, Hang
    Song, Yongping
    Jiang, Wenqi
    Sun, Xiuhua
    Qian, Wenbin
    Zhang, Wei
    Gao, Yuhuan
    Jin, Zhengming
    Zhou, Jianfeng
    Jin, Chuan
    Zou, Liqun
    Qiu, Lugui
    Li, Wei
    Yang, Jianmin
    Hou, Ming
    Zeng, Shan
    Liu, Peng
    Shi, Yuankai
    Zhou, Hui
    Wang, Shuyan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] A phase 2 study of a nivolumab (nivo)-containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): Study 205 Cohort D.
    Armand, Philippe
    Shipp, Margaret Ann
    Kuruvilla, John
    Collins, Graham P.
    Ramchandren, Rod
    Timmerman, John
    Sumbul, Anne
    Ruisi, Mary M.
    Kato, Kazunobu
    Ansell, Stephen Maxted
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial
    Brockelmann, Paul J.
    Goergen, Helen
    Keller, Ulrich
    Meissner, Julia
    Trautmann, Karolin
    Halbsguth, Teresa V.
    Sasse, Stephanie
    Sokler, Martin
    Kerkhoff, Andrea
    Mathas, Stephan
    Huttmann, Andreas
    Bormann, Matthias
    Zimmermann, Andreas
    Fuchs, Michael
    von Tresckow, Bastian
    Baues, Christian
    Rosenwald, Andreas
    Klapper, Wolfram
    Kobe, Carsten
    Borchmann, Peter
    Engert, Andreas
    BLOOD, 2020, 136
12345